Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARTERIAL VASCULAR ENGINEERING -- Ignore unavailable to you. Want to Upgrade?

To: Zeus549 who wrote (308)	11/22/1997 7:57:00 PM
From: Stuolson	Respond to of 339

In my opinion, its headed for a test of 40.

To: Zeus549 who wrote (308)	11/25/1997 5:45:00 PM
From: Jeff Gurian	Read Replies (1) \| Respond to of 339

Howdy Lee. Well, before today, I would have agreed with what you said in your previous post. Im sure you now know about the earnings estimate increase by now. Ive never seen such a big boost, that was nearly a 50% upwards increase. With earnings estimates higher, it gives some support to the higher PE, but it still does not quite justify a PE of 80. It might be supported by the PEG (price earnings to growth rate). PEGs are most often done by 4 to 5 year estimated earnings growth rates, though. If you or I can find out AVEs expected EPS in 2000-2002, I can run a PEG and tell you if the current price is justified. BTW, did you also see today that Boston Scientific took a hammering because they are not prepared enough to enter the stent market yet? Im not sure of the specifics, you would have to go to the newswire to get those, but its great news for AVE. If Im not on again in the next few days- have a happy Thanksgiving.